Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis

AL amyloidosis is an intractable disease resulting from a plasma cell dyscrasia which has a wide clinical spectrum. To investigate the phenotype of plasma cells in the bone marrow, a flow cytometric analysis was carried out in 10 patients with this disease (mean age, 57.8 ± 7.9 years) and controls w...

Full description

Saved in:
Bibliographic Details
Published in:Amyloid 2003, Vol.10 (2), p.110-116
Main Authors: Matsuda, Masayuki, Gono, Takahisa, Shimojima, Yasuhiro, Hoshii, Yoshinobu, Ikeda, Shu-Ichi
Format: Article
Language:English
Subjects:
ADP-ribosyl Cyclase - analysis
ADP-ribosyl Cyclase 1
Aged
AL amyloidosis
Amyloidosis - diagnosis
Amyloidosis - immunology
Antigens, CD - analysis
Antigens, CD19 - analysis
Bone Marrow - immunology
CD56 Antigen - analysis
Female
Flow Cytometry
Humans
Immunophenotyping
Male
Membrane Glycoproteins
Middle Aged
Myeloma Proteins - analysis
plasma cell
Plasma Cells - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AL amyloidosis is an intractable disease resulting from a plasma cell dyscrasia which has a wide clinical spectrum. To investigate the phenotype of plasma cells in the bone marrow, a flow cytometric analysis was carried out in 10 patients with this disease (mean age, 57.8 ± 7.9 years) and controls with M-protein (positive controls, n=4) and without it (negative controls, n=8). All patients were shown to have either Aκ- or A$LD-immunoreactive amyloid deposits on the biopsied tissues. On flow cytometry CD38++CD19+CD56-- cells (polyclonal plasma cells) showed no significant difference between patients (0.59 ± 0.37%) and either negative (2.25 ± 2.84%) or positive controls (0.38 ± 0.20%), while CD38++CD19-CD56+ cells (monoclonal plasma cells) showed a significantly higher level in the patients (1.34 ± 1.54%) than in either negative (0.041 ± 0.004%, p
ISSN:1350-6129
1744-2818
DOI:10.3109/13506120309041732